Participant flow16

How many started, completed or left each group, period by period.

1 to 16 of 16

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	177
Overall Study	STARTED	Almorexant 100mg	186
Overall Study	STARTED	Almorexant 200mg	176
Overall Study	STARTED	Zolpidem 10mg	168
Overall Study	Completed Double-blind Treatment	Placebo	163
Overall Study	Completed Double-blind Treatment	Almorexant 100mg	174
Overall Study	Completed Double-blind Treatment	Almorexant 200mg	171
Overall Study	Completed Double-blind Treatment	Zolpidem 10mg	161
Overall Study	COMPLETED	Placebo	161
Overall Study	COMPLETED	Almorexant 100mg	173
Overall Study	COMPLETED	Almorexant 200mg	170
Overall Study	COMPLETED	Zolpidem 10mg	159
Overall Study	NOT COMPLETED	Placebo	16
Overall Study	NOT COMPLETED	Almorexant 100mg	13
Overall Study	NOT COMPLETED	Almorexant 200mg	6
Overall Study	NOT COMPLETED	Zolpidem 10mg	9

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00608985/flow